Reported Earlier, Bayer's HYRNUO Wins First-Line FDA Approval For HER2-Mutated Lung Cancer, Following Priority Review And Breakthrough Therapy Designation
First-line approval of HYRNUO® (sevabertinib) for patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) follows U.S. Food and Drug Administration (FDA) Priority Review and Breakthrough Therapy
Bayer got permission to sell a new lung cancer medicine as a first treatment choice. When a company gets approvals like this, it shows the medicine works and could bring in money soon.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.